Selegiline and neuroprotection in Parkinson's disease
By: C. Warren Olanow, Peter Riederer, editors.
Contributors: Olanow, C. W. 1941-; Riederer, P.
Series: Neurology -- v. 47, no. 6, supplement 3 (December 1996); Neurology -- v. 47, no. 6.
Publisher: Little,Brown
Published: 1996
Place of publication: Boston, MA
Language: eng
Number of pages: 79
Subjects: Parkinson's disease -- Treatment.
Notes: Includes bibliographical references.
Table of contents: value: Pharmacology of selegiline / M. Gerlach ... [et al.]; value: The Natural history of Parkinson's disease / W.H. Poewe & G.K. Wenning; value: The Etiology of Parkinson's disease with emphasis on the MPTP story / J.W. Langston; value: Oxidative stress and the pathogenesis of Parkinson's disease / P. Jenner & C.W. Olanow; value: Modulation of gene expression rather than monamine oxidase inhibition: (-)-Deprenyl-related compounds in controlling neurodegeneration / W.G. Tatton & R.M.E. Chalmers-Redman; value: Is levodopa toxic? / S. Fahn; value: Selegiline monotherapy in the treatment of Parkinson's disease / W.C. Koller; value: Role of selegiline in combination therapy of Parkinson's disease / V.V. Myllylä ... [et al.]; value: Selegiline: current perspectives on issues related to neuroprotection and mortality / C.W. Olanow.